Relay Therapeutics Seeks $175M in Public Stock Offering
Event summary
- Relay Therapeutics plans to raise $175M through a public offering of common stock.
- Underwriters have a 30-day option to purchase an additional 15% of the shares.
- The offering is being made under a shelf registration statement filed with the SEC in August 2024.
- Proceeds will support the company's clinical-stage precision medicine pipeline.
The big picture
Relay Therapeutics' $175M offering reflects the ongoing need for clinical-stage biotech companies to secure non-dilutive capital to fund expensive drug development programs. The move comes amid a competitive landscape where precision medicine companies are racing to bring novel therapies to market, particularly in oncology and genetic diseases. The success of this offering will be closely watched as an indicator of investor appetite for high-risk, high-reward biotech investments.
What we're watching
- Market Conditions
- Whether favorable market conditions will allow Relay Therapeutics to complete the offering at the anticipated terms.
- Clinical Progress
- The pace at which Relay Therapeutics advances its lead asset, zovegalisib, through Phase 3 trials in metastatic breast cancer.
- Pipeline Execution
- How Relay Therapeutics allocates the proceeds to support its broader pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
Related topics